MATCH Results: Implications for the Internist

Slides:

Advertisements

Similar presentations

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Advertisements

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Frequency and Practice-Level Variation in Inappropriate.

Pierre Charbel Atallah, MD, Pierre Atallah, MD, Vikram Kashyap, MD

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Pneumothorax Recurrence Related to High-speed Lift

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

An Unusual Cause of Leg Ulcerations

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Introduction The American Journal of Medicine

Prevalence and Significance of Unrecognized Renal Dysfunction in Patients with Stroke David Pereg, MD, Zach Rozenbaum, MD, Dina Vorobeichik, MA, Nir Shlomo,

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD

Wandering Acute Myocardial Infarction

Todd A. Lee, PharmD, PhD, Brian Bartle, MPH, Kevin B. Weiss, MD, MPH

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Body Mass Index and Mortality in Acute Myocardial Infarction Patients

Trend in Mortality after Stroke with Atrial Fibrillation

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Laura Sarkisian, MD, Lotte Saaby, MD, PhD, Tina S

The Effect of a Statewide Smoking Ordinance on Acute Myocardial Infarction Rates Paul Basel, BS, Becki Bucher Bartelson, PhD, Marie Claire Le Lait, MS,

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Carotid Sinus Massage in Patients with Suspected Acute Myocardial Infarction, Tachycardia, and Left Bundle Branch Block Teddy Weiss, MD, Yair Elitzur,

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,

Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis Dharam J. Kumbhani, MD, SM, MRCP, Ph. Gabriel.

Andre J. Gauri, MD, Andrew Davis, MD, Thomas Hong, MD, Martin C

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

The Reply The American Journal of Medicine

TIA for the Internist The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Carlos Aguilar, MD, Valentin del Villar, MD

Truman J. Milling, MD, Alex C. Spyropoulos, MD

When Guidelines Cause Hypertension

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial Jill.

Repeated Hemoglobin A1C Ordering in the VA Health System

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Volume 371, Issue 9627, Pages (May 2008)

The Reply The American Journal of Medicine

Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis Kevin Bryan Lo, MD, Hafeez.

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Insomnia in the Elderly: Cause, Approach, and Treatment

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

Sharan Prakash Sharma, MD, Karleung Siu, MD

To Reduce Stroke with PFO Closure, Respect the Shunt

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Purnema Madahar, MD, Cristina M. Gonzalez, MD, MEd

One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta- analysis of Randomized Trials David S. Wald, MD, FRCP, Shahena Butt, MSc,

A Post-cure Complication

Plasma Lactescence in Acute Pancreatitis

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost- effectiveness analysis Mark D. Schleinitz, MS, MD, J.Peter Weiss, MS,

Brandon J. Patterson, PharmD, PhD, Debora A. Rausch, MD, Debra E

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Temporal trends in the incidence of coronary disease

Falls in Older Adults: Risk Assessment, Management and Prevention

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Significance of Comorbid Psychological Stress and Depression on Outcomes After Cardiac Rehabilitation Sergey Kachur, MD, Arthur R. Menezes, MD, Alban.

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Hypophosphatemia: Diagnostic Significance in Legionnaires’ Disease

Presentation transcript:

MATCH Results: Implications for the Internist Helmi L. Lutsep, MD The American Journal of Medicine Volume 119, Issue 6, Pages 526.e1-526.e7 (June 2006) DOI: 10.1016/j.amjmed.2005.10.047 Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 1 Kaplan-Meier curves for cumulative rates of primary end point events. (Reprinted with permission from Elsevier [The Lancet, 2004, Vol 364, pp 331–337].15) The American Journal of Medicine 2006 119, 526.e1-526.e7DOI: (10.1016/j.amjmed.2005.10.047) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 2 Rates and relative risks of primary end point event in prespecified subgroups. Although trends in favor of clopidogrel + aspirin were seen, no subgroup revealed a significant difference for the 2 treatment groups. IS = ischemic stroke; TIA = transient ischemic attack; MI = myocardial infarction; PAD = peripheral arterial disease; CI= confidence interval. (Reprinted with permission from Elsevier [The Lancet, 2004, Vol 364, pp 331–337.]15) The American Journal of Medicine 2006 119, 526.e1-526.e7DOI: (10.1016/j.amjmed.2005.10.047) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 3 Kaplan-Meier curves for cumulative rates of primary intracranial hemorrhage. (Reprinted with permission from Elsevier [The Lancet, 2004, Vol 364, pp 331–337].15) The American Journal of Medicine 2006 119, 526.e1-526.e7DOI: (10.1016/j.amjmed.2005.10.047) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 4 Treatment algorithm for secondary prevention of stroke.17,18 The American Journal of Medicine 2006 119, 526.e1-526.e7DOI: (10.1016/j.amjmed.2005.10.047) Copyright © 2006 Elsevier Inc. Terms and Conditions